Journal Article

Should We Reevaluate Antibiotic Breakpoints?

Mary Jane Ferraro

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 33, issue Supplement_3, pages S227-S229
Published in print September 2001 | ISSN: 1058-4838
Published online September 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/321852
Should We Reevaluate Antibiotic Breakpoints?

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The breakpoints used to interpret antimicrobial susceptibility tests should be carefully determined initially, using microbiological, pharmacokinetic, pharmacodynamic, and clinical data, and then reevaluated periodically as changes in bacterial resistance, susceptibility test methods, or antibiotic formulations occur. Throughout the world, different governmental agencies and professional organizations have responsibility for the initial establishment of antibiotic susceptibility breakpoints. In the United States, the National Committee for Clinical Laboratory Standards has a mechanism in place to establish breakpoints initially and to review and publish updates on an annual basis. There should be a continued effort to coordinate both susceptibility testing methods and breakpoint determinations in various parts of the world.

Journal Article.  1722 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.